- Home
- SHOT vs NRXP Comparison
SHOT vs NRXP Comparison
Compare SHOT & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- NRXP
- Stock Information
- Founded
- SHOT 2018
- NRXP 2015
- Country
- SHOT United States
- NRXP United States
- Employees
- SHOT N/A
- NRXP N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- NRXP Health Care
- Exchange
- SHOT Nasdaq
- NRXP Nasdaq
- Market Cap
- SHOT 30.4M
- NRXP 32.6M
- IPO Year
- SHOT 2020
- NRXP N/A
- Fundamental
- Price
- SHOT $0.29
- NRXP $2.64
- Analyst Decision
- SHOT
- NRXP Strong Buy
- Analyst Count
- SHOT 0
- NRXP 4
- Target Price
- SHOT N/A
- NRXP $28.50
- AVG Volume (30 Days)
- SHOT 2.0M
- NRXP 373.2K
- Earning Date
- SHOT 05-15-2025
- NRXP 05-15-2025
- Dividend Yield
- SHOT N/A
- NRXP N/A
- EPS Growth
- SHOT N/A
- NRXP N/A
- EPS
- SHOT N/A
- NRXP N/A
- Revenue
- SHOT $573,336.00
- NRXP N/A
- Revenue This Year
- SHOT N/A
- NRXP N/A
- Revenue Next Year
- SHOT N/A
- NRXP N/A
- P/E Ratio
- SHOT N/A
- NRXP N/A
- Revenue Growth
- SHOT 69.32
- NRXP N/A
- 52 Week Low
- SHOT $0.26
- NRXP $1.10
- 52 Week High
- SHOT $1.77
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- SHOT 27.09
- NRXP 63.84
- Support Level
- SHOT $0.26
- NRXP $2.47
- Resistance Level
- SHOT $0.45
- NRXP $2.72
- Average True Range (ATR)
- SHOT 0.05
- NRXP 0.25
- MACD
- SHOT -0.02
- NRXP 0.02
- Stochastic Oscillator
- SHOT 10.38
- NRXP 63.45
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.